The research landscape for tirzepatide (Mounjaro) continues to evolve rapidly. Beyond its established roles in weight management and type 2 diabetes, new studies are exploring a widening range of potential applications. Here is a summary of the most significant recent findings relevant to UK patients.
Sleep Apnoea Breakthrough
The SURMOUNT-OSA trial investigated tirzepatide in patients with obstructive sleep apnoea (OSA) and obesity. Results published in 2024-2025 demonstrated:
- A significant reduction in the apnoea-hypopnoea index (AHI), the primary measure of sleep apnoea severity
- Approximately 40-50% of participants saw their OSA severity category improve (e.g., from severe to moderate or moderate to mild)
- Improvements in sleep quality, daytime sleepiness, and blood oxygen levels
This is particularly relevant for UK patients, as an estimated 1.5 million adults in the UK live with untreated OSA.
Heart Failure With Preserved Ejection Fraction
Early-stage research is investigating tirzepatide's potential in heart failure with preserved ejection fraction (HFpEF), a condition strongly associated with obesity. Parallel studies with semaglutide (STEP-HFpEF) showed significant improvements in symptoms and exercise capacity, and similar benefits are hypothesised for tirzepatide.
NASH and Liver Disease
The SYNERGY-NASH trial results showed that tirzepatide achieved NASH resolution without worsening fibrosis in a significant proportion of patients. This positions tirzepatide as a potential treatment for a condition with no currently approved therapy in the UK, and Phase 3 trials are underway.
Weight Regain Prevention
New analyses from the SURMOUNT-4 study have provided detailed data on weight regain patterns after discontinuation. Researchers found that the rate and extent of regain varied significantly between individuals, with factors such as baseline BMI, age, and metabolic health influencing outcomes. This research is informing clinical guidelines on treatment duration.
Combination Therapy Approaches
Several research groups are now exploring tirzepatide in combination with other agents:
- Tirzepatide plus bimagrumab — to preserve lean muscle mass during weight loss
- Tirzepatide plus SGLT2 inhibitors — for enhanced cardiorenal protection in diabetes
- Tirzepatide plus behavioural interventions — assessing whether structured programmes improve long-term outcomes
Real-World Evidence
As tirzepatide use expands globally, real-world evidence studies are providing important data on effectiveness outside of controlled trial conditions. Early UK real-world data suggests that weight loss in clinical practice is broadly consistent with trial results, though adherence and persistence remain key factors.
What This Means for UK Patients
The breadth of tirzepatide research reflects its potential to address multiple obesity-related conditions simultaneously. For UK patients, this expanding evidence base may lead to broader NHS access criteria and new licensed indications over the coming years. Stay informed through reliable sources such as the MHRA, NICE, and evidence-based health platforms like MedsLens.